• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    MapLight Therapeutics, Inc. - Common Stock (NQ:MPLT)

    13.27 +0.27 (+2.08%)
    Streaming Delayed Price Updated: 12:42 PM EDT, Sep 14, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about MapLight Therapeutics, Inc. - Common Stock

    < Previous 1 2 Next >
    News headline image
    MapLight Therapeutics to Participate in Upcoming Investor Conference
    From MapLight Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    MapLight Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
    From MapLight Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    MapLight Therapeutics Announces $150 Million Private Placement Financing
    From MapLight Therapeutics, Inc.
    Via GlobeNewswire
    Top movers analysis one hour before the close of the markets on 2026-07-29: top gainers and losers in today's session. ↗
    Via Chartmill
    Traders are paying attention to the gapping stocks in Wednesday's session. ↗
    Via Chartmill
    Which stocks are moving on Monday? ↗
    Via Chartmill
    News headline image
    Maplight Therapeutics’ Schizophrenia Drug Hits Phase II Primary Endpoint ↗
    Maplight Therapeutics (NASDAQ:MPLT) reported that its Phase II ZEPHYR trial of ML-007C-MA met its primary endpoint in schizophrenia, with the twice-daily regimen producing a statistically significant... 
    Via MarketBeat
    Monday's session: top gainers and losers ↗
    Via Chartmill
    News headline image
    MPLT Investors Have Opportunity to Join MapLight Therapeutics, Inc. Fraud Investigation with SBS Law
    From Schall, Brown & Schwartz LLP
    Via Business Wire
    Let's uncover which stocks are experiencing notable gaps during today's session. ↗
    Via Chartmill
    These stocks that are showing activity before the opening bell on Monday. ↗
    Via Chartmill
    News headline image
    MapLight Therapeutics Announces Positive Topline Results from Phase 2 ZEPHYR Trial of ML-007C-MA in Schizophrenia
    From MapLight Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    MapLight Therapeutics Announces Changes to Board of Directors
    From MapLight Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    MapLight Announces Topline Results from Phase 2 IRIS Study for ML-004 in Autism Spectrum Disorder
    From MapLight Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Nan Fung Group Sells $4.3 Million in Oculis Shares As Lead Drug Stumbles ↗
    Oculis advances late-stage topical therapies for diabetic and neuro-ophthalmic eye diseases in the clinical-stage biotech sector. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Velan Capital Drops 140,000 Mineralys Therapeutics (MLYS) Shares Worth $4.1 Million ↗
    Mineralys Therapeutics develops novel therapies for resistant hypertension, with its lead candidate advancing through clinical trials. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Why This Fund Made a $66 Million Bet on Damora Therapeutics Amid a 700% Surge ↗
    This clinical-stage biotech develops small molecule therapies for cancer and fibrotic diseases, focusing on galectin-3 and LOXL2 inhibitors. 
    Via The Motley Fool
    News headline image
    Dyne Stock Is Up 56%. Here's What a $14 Million Stake Reduction Could Mean ↗
    Dyne Therapeutics targets rare muscle diseases with its FORCE platform, aiming to meet unmet needs in neuromuscular therapeutics. 
    Via The Motley Fool
    News headline image
    MapLight's CFO Just Sold 36,000 Shares for $1 Million. Is It a Buy, Sell, or Hold? ↗
    This clinical-stage biotech focused on CNS disorders reported a notable insider sale amid ongoing development of its neurology pipeline. 
    Via The Motley Fool
    Topics Derivatives Regulatory Compliance
    News headline image
    MapLight Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
    From MapLight Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    MapLight Therapeutics to Participate in Upcoming Investor Conferences
    From MapLight Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    This MapLight Insider Sold 69,000 Shares for $2.1 Million at the End of April ↗
    This clinical-stage biotech focused on CNS disorders reported a notable insider sale in its latest SEC filing. 
    Via The Motley Fool
    Topics Derivatives Regulatory Compliance
    News headline image
    MapLight Therapeutics Announces Completion of Enrollment in ZEPHYR Phase 2 Trial and Updates Expected Timing of Topline Results
    From MapLight Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    What a 1% Insider Sale of MPLT Stock Signals Ahead of 2026 Trial Data ↗
    This clinical-stage biotech focused on CNS disorders reported a notable insider sale, as disclosed in its latest SEC filing. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    MapLight Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
    From MapLight Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    MapLight Therapeutics to Participate in Upcoming Investor Conferences
    From MapLight Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    MapLight Therapeutics Updates Expected Timing of Topline Results for Ongoing Phase 2 Studies to Q3 2026
    From MapLight Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    MapLight Therapeutics Receives Fast Track Designation for ML-007C-MA for Alzheimer’s Disease Psychosis
    From MapLight Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    SandboxAQ and MapLight Therapeutics Announce Strategic Collaboration to Discover and Develop Novel CNS Therapies
    From MapLight Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    MapLight Therapeutics Reports Third Quarter Financial Results and Highlights Corporate Progress
    From MapLight Therapeutics, Inc.
    Via GlobeNewswire
    < Previous 1 2 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.